Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 4/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9278404 | 0.85 | TAAR1 (0.57) | AOC3TAAR1SIGMAR1FDPS | |
| SCHEMBL4482337 | 0.81 | CARM1 (0.55) | AOC3TAAR1SIGMAR1SLC6A2 | |
| Demelverine SCHEMBL1516521 | 0.80 | SIGMAR1 (0.76) | AOC3TAAR1SIGMAR1SLC6A2FDPS | |
| SCHEMBL9768687 | 0.78 | SIGMAR1 (0.73) | AOC3TAAR1SIGMAR1SLC6A2FDPS | |
| SCHEMBL28814049 | 0.77 | SIGMAR1 (0.49) | AOC3TAAR1SIGMAR1FDPS | |
| SCHEMBL20804036 | 0.77 | SIGMAR1 (0.49) | AOC3TAAR1SIGMAR1FDPS | |
| SCHEMBL12569401 | 0.76 | AOC3 (0.63) | AOC3TAAR1SIGMAR1 | |
| SCHEMBL8210535 | 0.75 | CARM1 (0.68) | AOC3TAAR1SIGMAR1SLC6A2FDPS | |
| SCHEMBL10145827 | 0.75 | AOC3 (0.61) | AOC3TAAR1SIGMAR1SLC6A2 | |
| SCHEMBL8402960 | 0.74 | SIGMAR1 (0.71) | AOC3TAAR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | HDAC1, HDAC11, HDAC2 | AOC3 1413/4885TAAR1 823/4885SIGMAR1 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.